Christopher D. Lao
University of Michigan · 175 works · 36,025 citations · h-index 53
Top works
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- Dose escalation of a curcuminoid formulation
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
- Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
- A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
- Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma